Clinical Trial

Finotonlimab Combined With Stapokibart in the Treatment of Recurrent/Metastatic HNSCC

Study acronym: LONG'E
Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
This is a single-arm, phase Ib study involving HNSCC patients who had received first-line treatment with either PD-1 combined with platinum-based drugs or PD-1 monotherapy. The aim of the study is to evaluate the safety and efficacy of Finotonlimab in combination with Stapokibart in the treatment of recurrent/metastatic HNSCC patients.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-06-19.
Status change: Not Yet Recruiting → Recruiting 2026-04-28
Trial Details
NCT Number NCT07040072
Lead Sponsor Beijing Tongren Hospital
Collaborators: Sinocelltech Ltd., Keymed Biosciences Co.Ltd
Conditions HNSCC
Enrollment 10 participants
Start Date 2025-10-09
Primary Completion 2027-06 (estimated)
Study Completion 2028-06 (estimated)
Updated on ClinicalTrials.gov 2026-05-04